Home > Biologic psoriasis treatment and COVID-19 risk: still a matter of debate

Biologic psoriasis treatment and COVID-19 risk: still a matter of debate

Presented By
Dr Anne-Claire Fougerousse; Dr Giovanni Damiani
Conference
EADV 2020
COVID-19 infections confront physicians with an ongoing number of puzzles. Two studies assessing the risk of developing COVID-19 for psoriasis patients treated with biologics presented contradictory results at the EADV Congress [1,2]. Systemic and biologic psoriasis treatments have been associated with an increased risk of infection. Thus, Dr Anne-Claire Fougerousse (Military Teaching Hospital Begin, France) and her team assessed the frequency of severe COVID-19 infections in psoriasis patients receiving systemic or biologic treatment, particularly during the 4 months following treatment initiation [1]. This national, multicentre, cross-sectional study included 1,418 adult psoriasis patients receiving systemic psoriasis treatment from 27 April to 7 May 2020. Besides data on the psoriasis treatment and the treatment period (initiation or maintenance), comorbidities like hypertension, obesity, and diabetes were collected. Where possible, probable cases of C...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on